First Japanese asset owner signs the Foundation’s investor statement
FOUNDATION AND INVESTORS
The Dai-ichi Life Insurance Company is the first Japanese asset owner to sign the investor statement of the Access to Medicine Foundation, becoming the 73rd signatory to pledge support to the Foundation’s research.
Thursday 14 September, 2018
Dai-ichi Life is the latest asset owner and the first Japanese life insurance company to publicly endorse and sign the investor statement of the Access to Medicine Foundation. As one of the largest life insurers in Japan, Dai-ichi Life manages assets of USD 342 billion.
Evaluating the growth potential of pharmaceutical companies
“We have decided to publicly endorse and sign the investor statement of the Access to Medicine Foundation because we believe that both pharmaceutical companies and investors have respective roles to play in improving access to medicine. As an institutional investor, we will use the Foundation’s research and analysis to gain insights into pharmaceutical companies’ performance in material ESG issues. We will apply those insights when evaluating the medium- and long-term growth potential of pharmaceutical companies and when engaging with those companies.”
Miyuki Zeniya, General Manager, Responsible Investment Center, The Dai-ichi Life Insurance Company, Limited.
Asset owners, including insurance companies and pension funds, play an important role in championing responsible investment and accelerating ESG integration across the investment chain. Globally more than 350 asset owners with USD 19 trillion of assets under management (AUM) have committed to the Principles for Responsible Investment (PRI). The Foundation is working with a number of these asset owners who consider access to medicine an important ESG issue and are incorporating it into their responsible investment process.
Investors managing over USD 10 trillion apply the Foundation’s research
Dai-ichi Life is the 73rd signatory to the Access to Medicine Foundation’s investor statement. Together, this group of signatory investors manage assets in excess of USD 10 trillion. As signatories, these investors commit to using the Access to Medicine Index in their investment research to compare how pharmaceutical companies manage risks and seize opportunities in emerging markets. They use the Foundation’s independent analysis of ongoing developments in the pharmaceutical sector to inform their dialogue with companies on important topics such as compliance, governance, pricing and R&D.